Children's Hospital of Alabama |
|
Birmingham, Alabama, United States, 35233 |
Banner Children's at Desert |
|
Mesa, Arizona, United States, 85202 |
Phoenix Childrens Hospital |
|
Phoenix, Arizona, United States, 85016 |
Arkansas Children's Hospital |
|
Little Rock, Arkansas, United States, 72202-3591 |
Kaiser Permanente Downey Medical Center |
|
Downey, California, United States, 90242 |
Loma Linda University Medical Center |
|
Loma Linda, California, United States, 92354 |
Miller Children's and Women's Hospital Long Beach |
|
Long Beach, California, United States, 90806 |
Children's Hospital Los Angeles |
|
Los Angeles, California, United States, 90027 |
Mattel Children's Hospital UCLA |
|
Los Angeles, California, United States, 90095 |
Valley Children's Hospital |
|
Madera, California, United States, 93636 |
UCSF Benioff Children's Hospital Oakland |
|
Oakland, California, United States, 94609 |
Kaiser Permanente-Oakland |
|
Oakland, California, United States, 94611 |
Lucile Packard Children's Hospital Stanford University |
|
Palo Alto, California, United States, 94304 |
UCSF Medical Center-Mission Bay |
|
San Francisco, California, United States, 94158 |
Children's Hospital Colorado |
|
Aurora, Colorado, United States, 80045 |
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center |
|
Denver, Colorado, United States, 80218 |
Yale University |
|
New Haven, Connecticut, United States, 06520 |
Alfred I duPont Hospital for Children |
|
Wilmington, Delaware, United States, 19803 |
Children's National Medical Center |
|
Washington, District of Columbia, United States, 20010 |
University of Florida Health Science Center - Gainesville |
|
Gainesville, Florida, United States, 32610 |
Nemours Children's Clinic-Jacksonville |
|
Jacksonville, Florida, United States, 32207 |
University of Miami Miller School of Medicine-Sylvester Cancer Center |
|
Miami, Florida, United States, 33136 |
Nicklaus Children's Hospital |
|
Miami, Florida, United States, 33155 |
Arnold Palmer Hospital for Children |
|
Orlando, Florida, United States, 32806 |
Nemours Children's Hospital |
|
Orlando, Florida, United States, 32827 |
Nemours Children's Clinic - Pensacola |
|
Pensacola, Florida, United States, 32504 |
Johns Hopkins All Children's Hospital |
|
Saint Petersburg, Florida, United States, 33701 |
Saint Joseph's Hospital/Children's Hospital-Tampa |
|
Tampa, Florida, United States, 33607 |
Saint Mary's Hospital |
|
West Palm Beach, Florida, United States, 33407 |
Children's Healthcare of Atlanta - Egleston |
|
Atlanta, Georgia, United States, 30322 |
Memorial Health University Medical Center |
|
Savannah, Georgia, United States, 31404 |
Kapiolani Medical Center for Women and Children |
|
Honolulu, Hawaii, United States, 96826 |
Saint Luke's Cancer Institute - Boise |
|
Boise, Idaho, United States, 83712 |
Lurie Children's Hospital-Chicago |
|
Chicago, Illinois, United States, 60611 |
University of Chicago Comprehensive Cancer Center |
|
Chicago, Illinois, United States, 60637 |
Saint Jude Midwest Affiliate |
|
Peoria, Illinois, United States, 61637 |
Riley Hospital for Children |
|
Indianapolis, Indiana, United States, 46202 |
Blank Children's Hospital |
|
Des Moines, Iowa, United States, 50309 |
University of Iowa/Holden Comprehensive Cancer Center |
|
Iowa City, Iowa, United States, 52242 |
Norton Children's Hospital |
|
Louisville, Kentucky, United States, 40202 |
Children's Hospital New Orleans |
|
New Orleans, Louisiana, United States, 70118 |
Ochsner Medical Center Jefferson |
|
New Orleans, Louisiana, United States, 70121 |
Eastern Maine Medical Center |
|
Bangor, Maine, United States, 04401 |
Sinai Hospital of Baltimore |
|
Baltimore, Maryland, United States, 21215 |
Johns Hopkins University/Sidney Kimmel Cancer Center |
|
Baltimore, Maryland, United States, 21287 |
C S Mott Children's Hospital |
|
Ann Arbor, Michigan, United States, 48109 |
Children's Hospitals and Clinics of Minnesota - Minneapolis |
|
Minneapolis, Minnesota, United States, 55404 |
University of Minnesota/Masonic Cancer Center |
|
Minneapolis, Minnesota, United States, 55455 |
Mayo Clinic in Rochester |
|
Rochester, Minnesota, United States, 55905 |
University of Mississippi Medical Center |
|
Jackson, Mississippi, United States, 39216 |
Children's Mercy Hospitals and Clinics |
|
Kansas City, Missouri, United States, 64108 |
Cardinal Glennon Children's Medical Center |
|
Saint Louis, Missouri, United States, 63104 |
Washington University School of Medicine |
|
Saint Louis, Missouri, United States, 63110 |
Mercy Hospital Saint Louis |
|
Saint Louis, Missouri, United States, 63141 |
Children's Hospital and Medical Center of Omaha |
|
Omaha, Nebraska, United States, 68114 |
University of Nebraska Medical Center |
|
Omaha, Nebraska, United States, 68198 |
University Medical Center of Southern Nevada |
|
Las Vegas, Nevada, United States, 89102 |
Alliance for Childhood Diseases/Cure 4 the Kids Foundation |
|
Las Vegas, Nevada, United States, 89135 |
Summerlin Hospital Medical Center |
|
Las Vegas, Nevada, United States, 89144 |
Hackensack University Medical Center |
|
Hackensack, New Jersey, United States, 07601 |
Morristown Medical Center |
|
Morristown, New Jersey, United States, 07960 |
Saint Peter's University Hospital |
|
New Brunswick, New Jersey, United States, 08901 |
Roswell Park Cancer Institute |
|
Buffalo, New York, United States, 14263 |
The Steven and Alexandra Cohen Children's Medical Center of New York |
|
New Hyde Park, New York, United States, 11040 |
Laura and Isaac Perlmutter Cancer Center at NYU Langone |
|
New York, New York, United States, 10016 |
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center |
|
New York, New York, United States, 10032 |
Memorial Sloan Kettering Cancer Center |
|
New York, New York, United States, 10065 |
NYP/Weill Cornell Medical Center |
|
New York, New York, United States, 10065 |
University of Rochester |
|
Rochester, New York, United States, 14642 |
State University of New York Upstate Medical University |
|
Syracuse, New York, United States, 13210 |
Mission Hospital |
|
Asheville, North Carolina, United States, 28801 |
Carolinas Medical Center/Levine Cancer Institute |
|
Charlotte, North Carolina, United States, 28203 |
Novant Health Presbyterian Medical Center |
|
Charlotte, North Carolina, United States, 28204 |
Duke University Medical Center |
|
Durham, North Carolina, United States, 27710 |
Children's Hospital Medical Center of Akron |
|
Akron, Ohio, United States, 44308 |
Cincinnati Children's Hospital Medical Center |
|
Cincinnati, Ohio, United States, 45229 |
Cleveland Clinic Foundation |
|
Cleveland, Ohio, United States, 44195 |
Nationwide Children's Hospital |
|
Columbus, Ohio, United States, 43205 |
Dayton Children's Hospital |
|
Dayton, Ohio, United States, 45404 |
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital |
|
Toledo, Ohio, United States, 43606 |
University of Oklahoma Health Sciences Center |
|
Oklahoma City, Oklahoma, United States, 73104 |
Legacy Emanuel Children's Hospital |
|
Portland, Oregon, United States, 97227 |
Oregon Health and Science University |
|
Portland, Oregon, United States, 97239 |
Geisinger Medical Center |
|
Danville, Pennsylvania, United States, 17822 |
Children's Hospital of Philadelphia |
|
Philadelphia, Pennsylvania, United States, 19104 |
Children's Hospital of Pittsburgh of UPMC |
|
Pittsburgh, Pennsylvania, United States, 15224 |
BI-LO Charities Children's Cancer Center |
|
Greenville, South Carolina, United States, 29605 |
Sanford USD Medical Center - Sioux Falls |
|
Sioux Falls, South Dakota, United States, 57117-5134 |
East Tennessee Childrens Hospital |
|
Knoxville, Tennessee, United States, 37916 |
Saint Jude Children's Research Hospital |
|
Memphis, Tennessee, United States, 38105 |
Vanderbilt University/Ingram Cancer Center |
|
Nashville, Tennessee, United States, 37232 |
Dell Children's Medical Center of Central Texas |
|
Austin, Texas, United States, 78723 |
Medical City Dallas Hospital |
|
Dallas, Texas, United States, 75230 |
UT Southwestern/Simmons Cancer Center-Dallas |
|
Dallas, Texas, United States, 75390 |
Cook Children's Medical Center |
|
Fort Worth, Texas, United States, 76104 |
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center |
|
Houston, Texas, United Stat
July 10, 2017
|
July 11, 2017
|
May 10, 2021
|
July 24, 2017
|
January 30, 2026 (Final data collection date for primary outcome measure)
|
Response rate [ Time Frame: From enrollment to the end of treatment, up to 2 years ] A responder is defined as a patient who achieves a best response of partial response (PR) or complete response (CR) on the study. Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method.
|
Response rate [ Time Frame: 4.5 years ] Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method.
|
|
- Number of participants with treatment-related adverse events as accessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 [ Time Frame: From enrollment to the end of treatment, up to 2 years ]
A patient will be counted only once for a given toxicity for the worst grade of that toxicity reported for that patient.
- Progression free survival (PFS) [ Time Frame: From the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause, assessed up to 5 years ]
Progression free survival will be defined as time from the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause. PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.
|
- Incidence of adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 4.5 years ]
Toxicity tables will be constructed to summarize the observed incidence by type of toxicity and grade. A patient will be counted only once for a given toxicity for the worst grade of that toxicity reported for that patient. Toxicity information recorded will include the type, severity, time of onset, time of resolution, and the probable association with the study regimen.
- Progression free survival (PFS) [ Time Frame: From the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause, assessed up to 4.5 years ]
PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.
|
- Biomarker analysis as predictors of response to selumetinib [ Time Frame: Up to 4.5 years ]
A descriptive analysis will be performed and will be summarized with simple summary statistics. All of these analyses will be descriptive in nature.
- Changes in tumor genomic profile [ Time Frame: Up to 4.5 years ]
A descriptive analysis will be performed and will be summarized with simple summary statistics. All of these analyses will be descriptive in nature.
|
Same as current
|
|
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
|
This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to other places in the body and have come back or do not respond to treatment. Selumetinib sulfate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
|
PRIMARY OBJECTIVE:
I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with selumetinib (AZD6244 hydrogen sulfate) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in the MAPK pathway.
SECONDARY OBJECTIVES:
I. To estimate the progression free survival in pediatric patients treated with selumetinib (AZD6244 hydrogen sulfate) with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor MAPK activation mutations.
II. To obtain additional information about the tolerability of selumetinib (AZD6244 hydrogen sulfate) in children with relapsed or refractory cancer.
EXPLORATORY OBJECTIVES:
I. To evaluate other biomarkers as predictors of response to selumetinib (AZD6244 hydrogen sulfate) and specifically, whether tumors that harbor different mutations or fusions will demonstrate differential response to selumetinib (AZD6244 hydrogen sulfate) treatment.
II. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).
OUTLINE:
Patients receive selumetinib sulfate orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
|
Interventional
|
Phase 2
|
Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
|
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- Recurrent Childhood Central Nervous System Neoplasm
- Recurrent Childhood Non-Hodgkin Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Neuroblastoma
- Refractory Malignant Solid Neoplasm
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Primary Central Nervous System Neoplasm
|
- Other: Laboratory Biomarker Analysis
Correlative studies
- Drug: Selumetinib
Given PO
Other Names:
- ARRY-142886
- AZD6244
- MEK Inhibitor AZD6244
- Drug: Selumetinib Sulfate
Given PO
Other Names:
- AZD-6244 Hydrogen Sulfate
- AZD6244 Hydrogen Sulfate
- AZD6244 Hydrogen Sulphate
- Koselugo
- Selumetinib Sulphate
|
Experimental: Treatment (selumetinib)
Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Interventions:
- Other: Laboratory Biomarker Analysis
- Drug: Selumetinib
- Drug: Selumetinib Sulfate
|
Not Provided
|
|
Active, not recruiting
|
49
|
Same as current
|
January 30, 2026
|
January 30, 2026 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
-
Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to molecular analysis for therapy choice (MATCH) to APEC1621E based on the presence of an actionable mutation
- Note: patients with BRAF V600 actionable mutations of interest (aMOIs) will be preferentially assigned to APEC1621G (vemurafenib) if that study is open and they are otherwise eligible for it
- Patients must have a body surface area >= 0.5 m^2 at enrollment
-
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice
- Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; Note: neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
-
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
- Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive: >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
- Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
- Corticosteroids: if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
- Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator
- Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)
-
Stem cell Infusions (with or without total body irradiation [TBI]):
- Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)
- Autologous stem cell infusion including boost infusion: >= 42 days
- Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)
-
X-ray therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation
- Note: radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment
- Radiopharmaceutical therapy (e.g., radiolabeled antibody, iodine I 131 metaiodobenzylguanidine [131I-MIBG]): >= 42 days after systemically administered radiopharmaceutical therapy
- Patients must not have received prior exposure to selumetinib (AZD6244 hydrogen sulfate)
-
For patients with solid tumors without known bone marrow involvement:
- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 within 7 days prior to enrollment
- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
- Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) within 7 days prior to enrollment >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:
- Age: 1 to < 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6
- Age: 2 to < 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8
- Age: 6 to < 10 years; maximum serum creatinine (mg/dL): male 1; female 1
- Age: 10 to < 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2
- Age: 13 to < 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4
- Age: >= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4
- Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age within 7 days prior to enrollment
- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L; (for the purpose of this study, the ULN for SGPT is 45 U/L) within 7 days prior to enrollment
- Serum albumin >= 2 g/dL within 7 days prior to enrollment
- Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study within 7 days prior to enrollment
- A blood pressure (BP) =< the 95th percentile for age, height, and gender measured within 7 days prior to enrollment; please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP; patients with hypertension controlled on antihypertensive medications will be allowed if otherwise eligible
- Serum triglyceride level =< 300 mg/dL within 7 days prior to enrollment
- Serum total cholesterol level =< 300 mg/dL within 7 days prior to enrollment
- Patients must be able to swallow intact capsules whole
- All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
Exclusion Criteria:
- Pregnant or breast-feeding women will not be entered on this study because there is currently no available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in girls who are post-menarchal; females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment; males with sexual partners who are pregnant or who could become pregnant (ie, women of child-bearing potential) should use effective methods of contraception for 12 weeks after completing the study to avoid pregnancy and/or potential adverse effects on the developing embryo
-
Concomitant medications
- Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
- Investigational drugs: patients who are currently receiving another investigational drug are not eligible
- Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible
- Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
- CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study
- CYP2C19 agents: patients who are currently receiving drugs that are strong CYP2C19 inducers (e.g., rifampin, ritonavir) or inhibitors (e.g.., fluoxetine, fluvoxamine, ticlopidine) are not eligible
- Patients who have an uncontrolled infection are not eligible
- Patients with known significant ophthalmologic conditions (uncontrolled glaucoma, history of retinal vein occlusion or retinal detachment, excluding patients with longstanding findings secondary to existing conditions) are not eligible
- Patients with low grade glioma are not eligible
- Patients who have received a prior solid organ transplantation are not eligible
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
|
Sexes Eligible for Study: |
All |
|
12 Months to 21 Years (Child, Adult)
|
No
|
Contact information is only displayed when the study is recruiting subjects
|
Puerto Rico, United States
|
|
|
NCT03213691
|
NCI-2017-01250 NCI-2017-01250 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) APEC1621E APEC1621E ( Other Identifier: Children's Oncology Group ) APEC1621E ( Other Identifier: CTEP ) U10CA180886 ( U.S. NIH Grant/Contract )
|
Yes
|
Studies a U.S. FDA-regulated Drug Product: |
Yes |
Studies a U.S. FDA-regulated Device Product: |
No |
|
Not Provided
|
National Cancer Institute (NCI)
|
National Cancer Institute (NCI)
|
Not Provided
|
Principal Investigator: |
Carl E Allen |
Children's Oncology Group |
|
National Cancer Institute (NCI)
|
May 2021
|
|